ARKG ARK Genomic Revolution ETF Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
17:16
Jul 06
Jul 06
The author notes that ARKG is showing strength with a 40% rally since June, but does not state a personal position or forward call.
LOW
20:37
Jul 01
Jul 01
Biotech benefits from AI tailwinds
Biotech is a downstream beneficiary of AI advances; several names have already rallied 15-20% since the last podcast and he remains very bullish.
MED
22:42
Jun 27
Jun 27
Buy genomics-focused ARK ETF as a midterm-year H2 healthcare/biotech seasonal rotation play; author names it alongside XBI as an "easy play" on the historical pattern.
MED
23:46
Jun 26
Jun 26
Buy ARKG as AI and memory technology adoption in healthcare and genomics drives a second-phase re-rating where fundamentals catch up to the narrative, moving beyond pure hype.
MED
14:30
Jun 26
Jun 26
Author believes the global correction may end soon as ETFs climb and volatility is short-lived, but remains cautious until QQQ reclaims a key gold zone.
LOW
16:27
Jun 25
Jun 25
The author suggests adding ARKG to a watchlist as a genome ETF to monitor, without expressing a personal bullish or bearish position.
LOW
16:44
Jun 24
Jun 24
ARK Genomics surged 8% in a breakout, with the author adopting a biotech approach inspired by Druckenmiller's "ape then research" philosophy while going live to discuss market positioning.
16:43
Jun 24
Jun 24
Watch ARKG as it breaks out of its base with strong momentum; author signals biotech is a current area of interest using a "buy first, research later" approach, but no explicit position disclosed.
MED
16:36
Jun 24
Jun 24
Long ARKG as it breaks out of its base; author explicitly frames the Druckenmiller "ape then research" approach as their current biotech strategy, signaling personal bullish positioning in the ETF.
MED
20:02
Jun 19
Jun 19
AI biotech megatrend, buy ARKG
AI is finally being applied to physical products and drug discovery, not just software. The FDA under RFK is becoming much more accommodating, as shown by the full U-turn on gene therapy. Avi bought ARKG (ARK Genomic Revolution ETF) with 3% of his portfolio and plans to increase exposure to genomics and biotech as this megatrend plays out.
HIGH
01:22
Jun 11
Jun 11
Avoid biotech due to insider market.
Longevity and biotech public market investments have historically underperformed because the best private companies get acquired by ultra-high-net-worth individuals at any price, leaving public investors with adverse selection. He explicitly stays away from ARKG and biotech stocks.
HIGH
00:57
Apr 25
Apr 25
Short indices after rally exhaustion
Index shorts on IWM, ARK, and QQQ are timely because the bear market rally is exhausted, short covering is fading, and the market remains vulnerable to the Iran war and private credit risks.
MED
00:58
Feb 28
Feb 28
Life Biosciences (private) reached an agreement with the FDA to treat humans with Yamanaka factors to reverse aging in the eye. This is the first human application of cellular rejuvenation technology. Success here validates the entire longevity/epigenetic reprogramming sector, likely sparking a boom in related public biotech stocks. WATCH. While the specific company is private, positive Phase 1 results will lift the entire genomics/longevity sector. Clinical trials fail or show adverse effects (e.g., cancer risk associated with cellular reprogramming).
MED
15:16
Feb 10
Feb 10
Anderson argues that the "Sunshine Genetics Act" solves the primary bottleneck for the industry: finding the patients. He notes the industry is projected to reach $100 billion. Big Pharma (specifically mentioning Merck) cannot justify investing in cures for diseases with only 16 patients due to ROI. However, by using state funds to de-risk early research and identify patients at birth (before symptoms), the state aggregates these "rare" cases into a large, investable asset class (30 million total people). This creates a "market" where none existed, inviting capital into the space. There are nearly 10,000 known rare diseases affecting 30 million Americans (more than the population of Texas or Florida). Regulatory hurdles and the high cost of gene therapies remain significant barriers to entry.
About ARKG Analyst Coverage
Buzzberg tracks ARKG (ARK Genomic Revolution ETF) across 8 sources. 7 bullish vs 1 bearish calls from 7 analysts. Sentiment: predominantly bullish (43%). 14 total trade ideas tracked. Latest voices: incomesharks, Avi Felman, wliang.